Document is current
Any future updates will be listed below
-
Authors
Jensen, Björn-Erik Ole https://orcid.org/0000-0003-1626-4855
Knops, Elena https://orcid.org/0000-0001-7398-3026
Cords, Leon https://orcid.org/0000-0003-1340-8817
Lübke, Nadine
Salgado, Maria https://orcid.org/0000-0003-1551-7216
Busman-Sahay, Kathleen https://orcid.org/0000-0002-8549-0023
Estes, Jacob D.
Huyveneers, Laura E. P.
Perdomo-Celis, Federico
Wittner, Melanie
Gálvez, Cristina
Mummert, Christiane
Passaes, Caroline https://orcid.org/0000-0002-0813-2521
Eberhard, Johanna M. https://orcid.org/0000-0002-8367-3870
Münk, Carsten
Hauber, Ilona
Hauber, Joachim
Heger, Eva
De Clercq, Jozefien
Vandekerckhove, Linos https://orcid.org/0000-0002-8600-1631
Bergmann, Silke
Dunay, Gábor A.
Klein, Florian https://orcid.org/0000-0003-1376-1792
Häussinger, Dieter https://orcid.org/0000-0002-5936-682X
Fischer, Johannes C.
Nachtkamp, Kathrin
Timm, Joerg https://orcid.org/0000-0001-7799-3045
Kaiser, Rolf
Harrer, Thomas
Luedde, Tom https://orcid.org/0000-0002-6288-8821
Nijhuis, Monique https://orcid.org/0000-0001-6610-8282
Sáez-Cirión, Asier https://orcid.org/0000-0003-2406-7536
Schulze zur Wiesch, Julian https://orcid.org/0000-0002-5033-1938
Wensing, Annemarie M. J.
Martinez-Picado, Javier https://orcid.org/0000-0002-4916-2129
Kobbe, Guido
- License Information
-
More Information
Article History
Received: 5 August 2022
Accepted: 9 January 2023
First Online: 20 February 2023
Competing interests
: B.-E.O.J. received honoraria for presentations from Gilead, ViiV Healthcare, MSD and Janssen (unrelated to the submitted work) and served on advisory boards for ViiV Healthcare and Gilead (unrelated to the submitted work). N.L. received honoraria for presentations from Gilead, MSD, Abbvie and ViiV Healthcare and served on the advisory boards for ViiV Healthcare and Theratechnologies (all unrelated to the submitted work). C. Münk received a research grant from Gilead (unrelated to the submitted work). I.H. and J.H. are cofounders and shareholders of PROVIREX Genome Editing Therapies GmbH, a start-up company focusing on the excision of HIV-1 by genome editing (unrelated to this work). J.S.z.W. received lecture fees from Gilead (unrelated to the submitted work). A.M.J.W. received an unrestricted research grant from Gilead and did consultancy for Gilead, GlaxoSmithKline and ViiV Healthcare (unrelated to the submitted work). J.M.-P. received institutional grants and educational/consultancy fees from AbiVax, AstraZeneca, Gilead, Grifols, Janssen, Merck Sharp & Dohme and ViiV Healthcare (unrelated to the submitted work). The other authors declare no competing interests.
